novo nordisk septerna - Search News

Order byBest matchMost fresh

News

Novo Nordisk Inks A Major Obesity Deal

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that could be worth up to $2.

Continue reading

· 12h · on MSN

· 11h · on MSN

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills

BioPharma Dive · 1h

Novo to work with Septerna in hunt for oral obesity drugs

Novo Nordisk strikes deal with Septerna to develop obesity pills

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

Indianapolis Business Journal8h

Novo Nordisk inks $2.2B deal to develop weight-loss pill to rival Lilly’s orforglipron

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results